CD22 and neoplasm: In that study, unlabelled anti-CD20 veltuzumab was administered to deplete the circulating B cells, enhancing biodistribution of the anti-CD22 radioconjugate 90Y-epratuzumab tetraxetan without interfering with tumour targeting.